Advertisements

Colchicina Seid

Quick links to important sections

Colchicina Seid

Advertisements
Advertisements

Method of action: Antigout, Anti-Inflammatory

Treatment option: Gout, Fits, Behcet Syndrome

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Colchicina Seid

Quick Facts

Property Description
Active ingredient Colchicine (INN)
Form Oral tablet (Comprimido)
Pharmacological class Antigout agent (M04AC01)
Common use Management of acute inflammatory episodes
Origin Plant-based alkaloid (Colchicum autumnale)

What is Colchicina Seid and What Type of Drug is it?

Colchicina Seid is a specialized, prescription-only medicinal product whose core component is the active ingredient Colchicine (INN). The drug is officially classified as an antigout agent, specifically designated within the ATC system as an antigout preparation not affecting uric acid metabolism. This classification highlights that the drug provides a distinct approach compared to therapies that aim to alter the body's production or excretion of uric acid. Its general purpose is to help control the intense, acute inflammation and resultant pain associated with conditions like gout attacks and chronic disorders such as Familial Mediterranean Fever (FMF).

The Composition of Colchicina Seid: Alkaloid, Origin, and Form

The product is a single-ingredient product, containing the alkaloid Colchicine (C22H25NO6). This compound is a plant-based derivative, historically sourced from the Colchicum autumnale plant. For oral administration, Colchicina Seid is supplied as a solid tablet (Comprimido). The use of colchicine is associated with the mitigation of painful symptoms during acute inflammatory episodes. The tablet formulation provides a standardized, convenient dosage form designed for reliable systemic absorption.

How Does Colchicine Relate to Acute Inflammation?

Colchicine is fundamentally an anti-inflammatory drug whose utility lies in its ability to intervene in the cellular processes that drive acute inflammation. Its primary action is centered on helping to control the cellular inflammatory cascade by affecting the mobility and function of key immune cells, such as neutrophils, thereby reducing their accumulation at the inflamed site. This effect ensures that the drug is particularly valuable for rapidly managing the painful and debilitating phases of inflammatory episodes through targeted cellular modulation.

Advertisements

What side effects are possible with Colchicina Seid?

Official Adverse Reactions and Safety Profile

The safety profile for Colchicine (Colchicina Seid) is clearly defined in regulatory documents and focuses on classifying adverse reactions by frequency and potential severity, while outlining critical restrictions. Colchicine possesses a narrow therapeutic window, meaning it has a high potential for toxicity, including fatal overdose, which is noted as a primary warning.

Frequency-Classified Side Effects

Adverse effects are categorized by how often they occur, as reported in regulatory documents. Gastrointestinal symptoms are the most frequent and are often considered the first sign of toxicity.

Classification Examples of Reactions Affected System-Organ Class
Very Common (ge 10%) Diarrhea Gastrointestinal Disorders
Common (ge 1% - < 10%) Nausea, Vomiting, Abdominal Pain Gastrointestinal Disorders
Rare (< 0.1%) Myopathy, Rhabdomyolysis, Alopecia Musculoskeletal, Skin

Serious Adverse Reactions

The official labeling highlights several serious, life-threatening risks, including severe Myelosuppression (blood disorders like Aplastic Anemia) and Rhabdomyolysis (muscle breakdown). Neuromuscular Toxicity is also officially recognized and has been associated with long-term exposure, even at therapeutic doses.

Population-Specific Safety Constraints

Specific safety warnings apply to certain groups. Regulatory documentation states that the risk of severe toxicity is significantly increased in Elderly Patients and those with existing Renal or Hepatic Impairment. The drug is officially Contraindicated for use in pregnancy and lactation, and in patients with organ impairment who are concurrently taking strong CYP3A4 or P-gp inhibitors.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Colchicine overdose is a serious medical emergency, and official regulatory documents mandate seeking urgent medical assessment for any suspected ingestion, even in the absence of initial symptoms. This is due to the potential for severe, delayed, and potentially fatal outcomes that progress over hours or days.

Early manifestations of toxicity typically occur 2 to 12 hours after ingestion, beginning with significant gastrointestinal distress, which includes profuse vomiting, severe abdominal pain, and often bloody diarrhea. These symptoms are critical and require immediate discontinuation of the drug and rapid escalation of care.

The toxicity progresses to a documented life-threatening, multi-system organ failure that can affect the blood system (myelosuppression), heart (myocardial depression), kidneys (acute failure), and liver. Fatal overdoses have been reported in both adults and children.

Management is strictly symptomatic and supportive, as no specific antidote is known for colchicine toxicity. Patients are required to undergo careful hospital monitoring for extended periods, especially following ingestion of high quantities. The official label notes an increased risk of severe toxicity in patients with pre-existing renal, hepatic, or cardiac impairment.

Advertisements

Therapeutic Uses of Colchicina Seid

Quick Facts: Uses of Colchicina Seid

  • Supports management of: Acute gout flares.
  • Assists in the prevention of: Recurring gout attacks.
  • Therapeutic utility in: Familial Mediterranean Fever (FMF).
  • May contribute to the reduction of risk for: Cardiovascular events in certain patient groups.

Colchicina Seid is a medication utilized in the management of specific inflammatory conditions. Its primary therapeutic domains involve addressing the symptoms and reducing the frequency of gout flares. Gout is a type of inflammatory arthritis associated with the accumulation of urate crystals in the joints. This medication is indicated for the treatment of acute gout flares and for the prophylaxis of recurrent attacks, particularly during the initiation of other uric acid-lowering treatments. Colchicina Seid also provides therapeutic benefit for the long-term control of Familial Mediterranean Fever (FMF), a hereditary inflammatory disorder, to help manage attacks and prevent associated complications.

In addition to these uses, a low-dose regimen of colchicine is used to help lower the risk of major adverse cardiovascular events, such as myocardial infarction (heart attack) and stroke, in adult patients who have established atherosclerotic cardiovascular disease or multiple associated risk factors. This represents a preventative application for individuals with elevated cardiovascular concern.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Colchicina Seid?

The eligibility for Colchicina Seid (colchicine) is strictly defined by regulatory authorities and depends on the patient's condition, age, and organ function.

Contraindicated Populations (Must Not Use):

Criteria Population Restriction
Organ Impairment Patients with severe renal or severe hepatic impairment.
Drug Interactions Patients with any renal or hepatic impairment who are concurrently taking a P-gp or strong CYP3A4 inhibitor.
Physiological State Women who are pregnant or breastfeeding (as per many national agencies).
Blood Disorders Patients with pre-existing severe blood dyscrasias (e.g., bone marrow depression).

Approved and Restricted Use:

  • Adults: Approved for the management of gout flares and for cardiovascular risk reduction in eligible patients.
  • Children and Adolescents: Approved for Familial Mediterranean Fever (FMF) in patients 4 years of age and older. Use for gout is generally not recommended in pediatric patients.
  • Geriatric Patients: Requires close monitoring due to an increased risk of toxicity linked to common decreases in renal function.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Colchicina Seid (colchicine) has officially documented interaction patterns primarily involving two major elimination pathways: the Cytochrome P450 3A4 (CYP3A4) enzyme for metabolism and the P-glycoprotein (P-gp) efflux transporter. Both are substrates for colchicine clearance.

Pharmacokinetic and Contraindicated Interactions

Co-administration with medicines classified as inhibitors of CYP3A4 and/or P-gp is documented to increase the systemic exposure to colchicine, which raises the risk of toxicity. This includes strong inhibitors such as clarithromycin, ketoconazole, and certain protease inhibitors.

The combination with strong inhibitors of CYP3A4 and/or P-gp is formally contraindicated in patients with pre-existing renal or hepatic impairment due to the heightened risk of life-threatening drug accumulation, a restriction explicitly stated in regulatory labeling.

Pharmacodynamic Interactions and Substance Restrictions

A separate interaction involves substances that increase the risk of neuromuscular toxicity. When colchicine is co-administered with HMG-CoA Reductase Inhibitors (Statins) or Fibrates, there is a documented increase in the risk of severe muscle symptoms, including rhabdomyolysis.

Regarding substances, the consumption of grapefruit or grapefruit juice is restricted, as it inhibits CYP3A4 and is documented to increase colchicine plasma concentrations.

Advertisements

Mechanism of Action

Colchicina Seid works primarily through its selective binding to beta-tubulin subunits within the cell cytoplasm. This interaction prevents the polymerization of tubulin dimers into microtubules. The resulting disruption of the microtubule structure is fundamental to its cellular mechanism.

This depolymerization process inhibits the critical functions of highly mobile immune cells, particularly neutrophils and macrophages, including their motility, adhesion, and degranulation. The mechanism also involves the intracellular inhibition of the NLRP3 inflammasome complex. By interfering with NLRP3 activation, the drug suppresses the proteolytic processing and subsequent release of highly active interleukin-1beta (IL-1beta) and other pro-inflammatory cytokines. The ultimate system-level physiological consequence of these molecular events is the reduction of inflammatory cell migration and subsequent modulation of the localized inflammatory cascade.

Advertisements

Dosage and Administration Information

Colchicina Seid, whose active component is colchicine, is strictly intended for oral administration as a tablet. The medicine may be taken without regard to meals, meaning intake is not dependent on the timing of food consumption. If a dose is missed during a scheduled regimen, the missed dose is typically taken as soon as possible, but the next scheduled dose must not be doubled.

Standard dosing protocols are distinctly structured based on the intended use. For the treatment of an acute gout flare, the typical course with the 1 mg tablet involves taking 1 mg at the first sign of an attack, followed by 1 mg one to two hours later, with a maximum cumulative dose of 2 mg in 24 hours. Prophylaxis (prevention) and maintenance use for conditions like Familial Mediterranean Fever (FMF) typically follow a daily schedule, ranging from 0.6 mg to 1 mg per day, taken either as a single daily dose or in divided doses. A full acute course must not be repeated until at least 3 days have passed since the completion of the last course. Specific protocols for certain patient populations indicate that those with moderate renal impairment (CrCl 30-50 ml/min) receive a reduced dose and/or an increased interval between doses.

Advertisements

Recent Clinical Evidence

Evidence for Use in Acute Gout Flares

The medication was evaluated in short-term Randomized Controlled Trials (RCTs) for sudden gout flares. Studies examined outcomes related to physical discomfort, such as pain intensity and joint swelling. The findings describe patterns observed in the studies regarding the measured changes in symptoms. Follow-up durations were limited, meaning the research provides limited insight into response after the first few days of the episode.

Evidence for Prophylaxis of Gout Attacks

Research utilized placebo-controlled RCTs to explore the role of this medicine in preventing future gout episodes, particularly for patients starting urate-lowering treatments. Trials monitored the number of new gout flares occurring over the study period. Studies report that the approach did not meet the criteria for formal gout remission definitions after the prophylactic period concluded.

Evidence for Management of Familial Mediterranean Fever (FMF)

This medication was studied for its application in managing chronic FMF attacks. The evidence base includes older controlled trials and extensive long-term observational research. Studies examined outcomes like the frequency of attacks and the incidence of secondary inflammatory complications like amyloidosis. Evidence is limited for outcomes in very young children across all regulatory frameworks.

Evidence for Cardiovascular Risk Reduction

Low-dose colchicine was evaluated in large-scale, placebo-controlled RCTs for patients with established atherosclerotic cardiovascular disease. These trials monitored the incidence of Major Adverse Cardiovascular Events (MACE). Findings were mixed when assessing the impact solely on the endpoints of all-cause death or cardiovascular death.


Long-Term Studies and Follow-up

Long-term studies for FMF and gout prophylaxis contribute to understanding sustained management. However, research for acute flares is short-term. The long-term maintenance of measured changes and extended-duration data are not fully established beyond the several years of the pivotal cardiovascular trials.

Evidence in Special Populations

The research examined specific patient groups, including children with FMF and older adults in gout and cardiovascular trials. However, data for certain groups remain limited. Research describes that results apply only to the populations studied.

What Is Still Uncertain About Colchicina Seid Research

Research highlights what is known — and what is still uncertain. Evidence quality varies across studies, and findings were mixed or inconsistent for specific critical outcomes (e.g., mortality). Comparative evidence is lacking for some of the newer treatment approaches. Data are still emerging for certain indications and patient subgroups.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Colchicina Seid (FAQ)


Q: Is Colchicina Seid the same as the colchicine I heard about?

A: Colchicina Seid is a specific brand-name prescription product that contains the active ingredient colchicine. Colchicine is the standardized chemical compound used in other generic and brand-name formulations across the globe. Therefore, Colchicina Seid is a specific version of the medicine you may have heard discussed in general terms.


Q: How quickly should I expect Colchicina Seid to start working for a flare-up?

A: Regulatory documents describe that the medicine is readily absorbed following oral intake. Data from studies examining the drug's processing in the body indicate that the active component, colchicine, may achieve its highest concentrations in the blood within approximately three hours in healthy adults.


Q: Is Colchicina Seid considered a pain reliever?

A: According to official documentation, Colchicina Seid (colchicine) is not classified as an analgesic medicine (a typical pain reliever). Its purpose is to manage inflammation in specific conditions. Regulatory documents state that its use is not indicated for the treatment of pain unrelated to its approved conditions.


Q: What kind of foods or supplements should be discussed with a doctor when taking Colchicina Seid?

A: Official information advises patients to inform their healthcare provider about all medications, non-prescription medicines, and herbal supplements they are taking. This review is important because many products may interfere with the metabolic and elimination pathways of colchicine. Grapefruit and grapefruit juice are specifically restricted because they are documented to increase the amount of colchicine in the body.


Q: Can Colchicina Seid affect fertility in men or women?

A: Official labeling advises that colchicine may rarely and transiently impair fertility in males. Nonclinical studies and case reports have described effects on sperm count and shape, which were reported to be reversible once the medicine was stopped. Fertility concerns related to the medication should be addressed with a healthcare provider.


Q: How does the colchicine in Colchicina Seid compare to herbal remedies that contain colchicine?

A: Colchicina Seid is a prescription-only, pharmaceutical product that contains a precisely measured, standardized dose of colchicine. The regulatory documents and safety warnings for a manufactured product apply specifically to that pharmaceutical formulation. Unlike the pharmaceutical product, the concentration of active ingredients in herbal remedies can vary significantly.


Q: What if I forget to take my Colchicina Seid?

A: Official instructions for a scheduled regimen advise that if a dose is missed, the patient should take the missed dose as soon as possible, then continue with the next dose at the usual time. Official instructions advise that the patient should not take a double dose to compensate for a dose that was missed.


Q: What should I do if I experience nausea after taking Colchicina Seid?

A: Nausea, vomiting, and diarrhea are common gastrointestinal effects. If these common symptoms occur, regulatory information indicates this may be a sign of a dose that is too high. Any adjustments to the dose are determined by the prescribing physician.


Q: Does Colchicina Seid cause hair loss?

A: The official adverse reaction documentation includes Alopecia, which is the medical term for hair thinning or loss. This effect is categorized as a Rare side effect, meaning it is reported in less than 0.1% of patients.


Q: Is it known if Colchicina Seid causes drowsiness or affects driving?

A: While drowsiness is not listed as a common effect in official adverse event summaries, safety warnings advise patients to contact a healthcare provider if they experience signs of severe reactions, which can include confusion or dizziness. Any sudden onset of these symptoms is typically communicated to a healthcare provider.


Q: How is Colchicina Seid typically stored?

A: Official product information requires that the product be stored in the original container to protect it from light and moisture. It should be kept at room temperature, typically between 20 C to 25 C (68 F to 77 F). For safety, it is a requirement that the product be kept out of the reach of children.


Q: Is there a specific time of day recommended for taking Colchicina Seid?

A: Official administration instructions permit taking the total daily dose as a single or divided dose (e.g., once or twice daily), depending on the treatment regimen. Regulatory documents do not mandate a specific time of day, but the medicine is taken according to the specific directions provided by the prescriber.


Q: Do other medications need to be stopped when starting Colchicina Seid?

A: Official labeling details severe interactions with specific classes of medicines that inhibit certain metabolic pathways (CYP3A4 or P-gp), as well as with other drugs like Statins and Fibrates. Because of these risks, the prescribing physician reviews all co-administered medicines to determine if any changes are necessary.


Q: Does Colchicina Seid have the potential to interact with herbal supplements like St. John's Wort?

A: Regulatory-related review information reports that the herbal supplement St. John's wort has the potential to interact with colchicine. This interaction is described as potentially reducing the effectiveness of colchicine due to St. John's wort's effects on the drug's metabolic pathway.


Q: Can I take Colchicina Seid if I am already taking medicine for high blood pressure?

A: Official documentation does not prohibit the medicine with all high blood pressure treatments. However, many drugs, including some used for blood pressure, can be CYP3A4 or P-gp inhibitors, which can lead to increased colchicine levels. A comprehensive review of all current medications by the prescriber is performed to identify potential interactions.


Q: Are there any official reports of serious reactions to Colchicina Seid?

A: Yes, official labeling highlights several serious, life-threatening risks that have been reported in patients. These include severe Myelosuppression (blood disorders), Rhabdomyolysis (muscle breakdown), and the overall risk of Fatal Overdose.


Q: Why are there different strengths of Colchicina Seid tablets?

A: Different tablet strengths, such as the commonly used 0.6 mg, exist to allow the prescribing physician to adjust the daily dosage to meet various recommended dosing schedules. These schedules differ for treating an acute flare versus maintenance therapy and help accommodate patients with certain organ impairments.


Q: How long does Colchicina Seid stay in the body after the last dose?

A: Pharmacokinetic data from official sources indicate that the drug has a long mean elimination half-life in healthy young adults, typically ranging from 26.6 to 31.2 hours. This means that it can take several days for the drug to be substantially cleared from the body after the last dose.


Q: How is the need for continued Colchicina Seid treatment determined?

A: The duration of treatment is determined by the specific condition being managed. For the prevention of gout, it is often recommended for a minimum of the first six months. For chronic conditions like FMF, the treatment may be continued, with the overall goal being to control the disease and as tolerated.


Q: What are the main risks associated with Colchicina Seid use?

A: Official documentation details that the main risks include the potential for severe, life-threatening effects such as Myelosuppression (a serious blood disorder), Rhabdomyolysis (severe muscle damage), Neuromuscular Toxicity, and the risk of Fatal Overdose due to its narrow therapeutic window.


Q: Is Colchicina Seid safe for older adults (seniors)?

A: Official documentation states that older adults are at an increased risk of toxicity, even with normal liver and kidney function, and may have a stronger reaction to the medicine. Therefore, its use is described as requiring close monitoring due to these concerns.


Q: Can people with kidney issues use Colchicina Seid?

A: Use is contraindicated in patients with severe kidney impairment who are also taking certain interacting medicines. For patients with mild to moderate kidney impairment, official documentation states that adjustment of dosing is often required, and official information notes that close monitoring is typically utilized due to the increased toxicity risk.


Q: Does Colchicina Seid interact with common over-the-counter pain medications?

A: Official documents caution against co-administration with drugs that increase the risk of neuromuscular toxicity, such as the prescription drugs Statins and Fibrates. While specific non-prescription pain relievers are not directly addressed in this warning, all co-administered medicines must be reviewed by the prescriber.


Q: Can Colchicina Seid be used by children?

A: Official documentation specifies that the drug is approved for the management of Familial Mediterranean Fever (FMF) in patients 4 years of age and older. Use for gout is generally not recommended in pediatric patients.


Q: Is there an age limit mentioned in regulatory documents for Colchicina Seid use?

A: The regulatory documents specify that the medicine is approved for use in children with Familial Mediterranean Fever (FMF) who are 4 years of age and older. While there is no upper age limit, use in older adults is permitted but requires close monitoring due to an increased risk of toxicity.


Q: How does Colchicina Seid differ from NSAIDs?

A: Colchicina Seid is classified as an anti-inflammatory agent that works by disrupting microtubules and inhibiting the function of certain immune cells. It is not an NSAID (non-steroidal anti-inflammatory drug). NSAIDs work through a different process by inhibiting cyclooxygenase (COX) enzymes to reduce inflammation.


Q: What is the official chemical name for the active ingredient in Colchicina Seid?

A: The active ingredient in Colchicina Seid is colchicine. The full official chemical name described in regulatory sources is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide.


Q: What happens if Colchicina Seid is taken in too large an amount?

A: Official documentation strictly warns that taking too large an amount can lead to life-threatening and potentially fatal toxicity in both adults and children. The drug has a narrow therapeutic window, and the highest risk is associated with Fatal Overdose.

Advertisements

How should Colchicina Seid be stored and disposed of?

Storage and Disposal of Colchicina Seid

Storage of Colchicina Seid (Colchicine tablets) must strictly adhere to regulatory requirements to maintain product integrity and safety.


Official Storage Conditions

Requirement Specific Condition
Temperature Must not be stored above 25°C (77°F); store at 20 C to 25 C.
Protection Store in the original container and protect from light and moisture.
Container Keep the container tightly closed; store the blister in the outer carton.
Shelf Life Labeled shelf life is typically five years.

Handling and Disposal

The medication must be stored out of the reach of children, as this is a critical safety requirement. Disposal of any unused or expired Colchicina Seid must follow local requirements for pharmaceutical waste. Medicines should not be discarded into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colchicina Seid found in:

A-Z Index: